Clinical Impact of 123I-Ioflupane SPECT (DaTscan) in a Movement Disorder Center

被引:12
|
作者
Graebner, Allison K. [1 ]
Tarsy, Daniel [1 ]
Shih, Ludy C. [1 ]
Vanderhorst, Veronique [1 ]
Kulkarni, Omesh [1 ]
Kaplan, Scott [1 ]
Simon, David K. [1 ]
机构
[1] Harvard Med Sch, Parkinsons Dis & Movement Disorders Ctr, Beth Israel Deaconess Med Ctr, 330 Brookline Ave,Room CLS 638, Boston, MA 02215 USA
关键词
Parkinson's disease; Parkinsonism; DaTscan; Neuroimaging; Biomarker; Nigrostriatal system; Neurodegeneration; DAT-SPECT; DIAGNOSIS; ACCURACY; DISEASE;
D O I
10.1159/000447561
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background/Aims: The clinical diagnosis of degenerative forms of parkinsonism is imperfect, with past studies reporting a high rate of misdiagnosis by neurologists and movement disorder specialists, particularly early in the disease course. 123 I-ioflupane SPECT (DaTscan) is a diagnostic neuro-imaging tool used to distinguish essential tremor from tremor due to degenerative parkinsonisms. The present study expands upon prior studies of the clinical impact of DaTscan imaging in movement disorder centers by assessing quantitative estimates of diagnostic certainty, the impact on subsequent clinical decisions, and the degree to which the asymmetry in the results corresponds to laterality by clinical history and examination. Methods: In a prospective, observational study of the impact of DaTscan imaging in a movement disorder center over the course of 18 months, 4 specialists completed a questionnaire at the time they ordered imaging and again within 1 month after imaging. Results: Twenty-seven patients underwent DaTscan imaging; the result was normal in 4 cases (14.8%), abnormal in 22 cases (81.4%), and equivocal in 1 case (3.7%). In all cases of a normal result, the post-scan-predicted chance of degenerative parkinsonism decreased compared to the pre-scan prediction (p < 0.05), and in all cases of abnormal scan, the postscan chance of degenerative parkinsonism increased or remained high (p < 0.0001). Clinical impacts were observed following imaging in a total of 24 patients (88.9%), including changes in medications for 18 patients and psychological impacts for 11 patients. Asymmetric clinical symptoms were corroborated based on the expected asymmetry of dopamine uptake deficits in 57.1% of the cases, were not present in 23.8%, and were opposite of expectations in 19.0% of the scans. Conclusion: DaTscan imaging results have an impact on physician's confidence in the diagnosis of parkinsonism and may also have a psychological impact on patients. DaTscan imaging may be a useful adjunct to clinical history and examination in selected patients. (C) 2016 S. Karger AG, Basel
引用
收藏
页码:38 / 43
页数:6
相关论文
共 50 条
  • [31] Bipolar Disorder and Parkinson's Disease: A 123I-Ioflupane Dopamine Transporter SPECT Study
    Erro, Roberto
    Landolfi, Annamaria
    D'Agostino, Giulia
    Pace, Leonardo
    Picillo, Marina
    Scarano, Massimo
    Cuocolo, Alberto
    Pappata, Sabina
    Vitale, Carmine
    Pellecchia, Maria Teresa
    Monteleone, Palmiero
    Barone, Paolo
    FRONTIERS IN NEUROLOGY, 2021, 12
  • [32] Effect of brain atrophy in quantitative analysis of 123I-ioflupane SPECT
    Hayashi, Toshiyuki
    Mishina, Masahiro
    Sakamaki, Masanori
    Sakamoto, Yuki
    Suda, Satoshi
    Kimura, Kazumi
    ANNALS OF NUCLEAR MEDICINE, 2019, 33 (08) : 579 - 585
  • [33] Is There Any Clinical Value of Adding 123I-Metaiodobenzylguanidine Myocardial Scintigraphy to 123I-Ioflupane (DaTscan) in the Differential Diagnosis of Parkinsonism?
    Stathaki, Maria
    Koukouraki, Sophia
    Simos, Panagiotis
    Boura, Iro
    Papadaki, Emmanouela
    Bourogianni, Olga
    Tsaroucha, Angeliki
    Kapsoritakis, Nikolaos
    Mitsias, Panayiotis
    Spanaki, Cleanthe
    CLINICAL NUCLEAR MEDICINE, 2020, 45 (08) : 588 - 593
  • [34] Effectiveness of 123I-ioflupane (DaTSCAN®) in the diagnosis of parkinsonian syndromes.: A systematic review
    Rioboo, J. Punal
    Lema, L. Varela
    Puig, A. Serena
    Ruano-Ravina, A.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR, 2007, 26 (06): : 375 - 384
  • [35] Elaboration of the SPM template for the standardization of SPECT images with 123I-Ioflupane
    Garcia-Gomez, F. J.
    Garcia-Solis, D.
    Luis-Simon, F. J.
    Marin-Oyaga, V. A.
    Carrillo, F.
    Mir, P.
    Vazquez-Albertino, R. J.
    REVISTA ESPANOLA DE MEDICINA NUCLEAR E IMAGEN MOLECULAR, 2013, 32 (06): : 350 - 356
  • [36] Effect of brain atrophy in quantitative analysis of 123I-ioflupane SPECT
    Toshiyuki Hayashi
    Masahiro Mishina
    Masanori Sakamaki
    Yuki Sakamoto
    Satoshi Suda
    Kazumi Kimura
    Annals of Nuclear Medicine, 2019, 33 : 579 - 585
  • [37] Optimizing the Diagnosis of Parkinsonian Syndromes With 123I-Ioflupane Brain SPECT
    Banks, Kevin P.
    Peacock, Justin G.
    Clemenshaw, Michael N.
    Kuo, Phillip H.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2019, 213 (02) : 243 - 253
  • [38] A longitudinal follow-up study of the quantification of dopamine transporters with 123I-Ioflupane (DaTscan)
    Fayolle, H.
    Gantet, P.
    Salabert, A. S.
    Delrieu, J.
    Brefel-Courbon, C.
    Ory-Magne, F.
    Voisin, T.
    Payoux, P.
    MEDECINE NUCLEAIRE-IMAGERIE FONCTIONNELLE ET METABOLIQUE, 2017, 41 (01): : 36 - 41
  • [39] 123I-ioflupane FP-CIT (DaTSCAN) in differential diagnosis of Parkinson's disease
    Brajkovic, L.
    Svetel, M.
    Kostic, V.
    Stefanova, E.
    Petrovic, I.
    Stojkovic, T.
    Pavlovic, S.
    Sobic-Saranovic, D.
    Artiko, V.
    Obradovic, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2010, 37 : S401 - S401
  • [40] 123I-ioflupane SPECT scan in a patient with Creutzfeldt-Jakob Disease
    Mazzoleni, R.
    Vanderheyden, J. E.
    Delcourt, E.
    Sellitti, E.
    Noel, S.
    Seeldrayers, P.
    ACTA NEUROLOGICA BELGICA, 2010, 110 (01) : 118 - 119